文献速递淋巴瘤造血干细胞移植与细胞治疗

CAR-T治疗前后实践模式及侵袭性B细胞非霍奇金淋巴瘤患者CAR-T失败后生存预测因素的多中心回顾性分析

Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL.
PubMed 文献 · Blood Adv · 2023-01-01

该多中心回顾性分析纳入2015-2021年间13个中心接受CD19 CAR-T治疗的侵袭性B细胞非霍奇金淋巴瘤患者514例,描述CAR-T围治疗期实践模式并分析生存预测因素。结果显示CAR-T输注后中位无进展生存期7.6个月、总生存期25.6个月;CAR-T失败后中位总生存期5.5个月,首次失败后治疗的中位无进展生存期2.8个月。

要点

  • CAR-T前接受更多线治疗和桥接治疗可预测更差的无进展生存期和总生存期。
  • CAR-T输注后中位无进展生存期7.6个月,中位总生存期25.6个月。
  • CAR-T失败后中位总生存期5.5个月,首次失败后治疗的中位无进展生存期2.8个月。

核心结论

  • 对于接受CAR-T治疗的侵袭性B细胞非霍奇金淋巴瘤患者,CAR-T前更多线治疗和桥接治疗可预测更差的无进展生存期和总生存期。
  • 这些数据为CAR-T后进展患者的未来临床试验提供了基准,该人群仍存在未满足的临床需求。

研究设计与样本

  • 多中心回顾性分析,纳入2015-2021年间13个中心接受CD19 CAR-T治疗的侵袭性B细胞非霍奇金淋巴瘤患者514例。
  • 采用Kaplan-Meier法构建生存曲线,多因素Cox回归分析变量对生存结局的影响。

主要发现

  • CAR-T输注后中位无进展生存期为7.6个月,中位总生存期为25.6个月。
  • CAR-T后进展时起中位总生存期为5.5个月。
  • CAR-T失败后一线治疗的中位无进展生存期为2.8个月。
  • 第30天难治性疾病患者总生存期更差,且较其他CAR-T失败患者更少接受后续治疗。
  • 对筛选患者在CAR-T失败后任何时间接受异基因造血细胞移植,超过半数患者在1年时获得持久缓解。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Most patients receiving chimeric antigen receptor T-cell therapy (CAR-T) for aggressive B-cell non-Hodgkin lymphoma (B-NHL) do not experience a durable remission. Several novel agents are approved to treat relapsed, refractory aggressive B-NHL; however, it remains unclear how to sequence these therapies pre- and post-CAR-T. We conducted a multicenter retrospective analysis to describe peri-CAR-T practice patterns and survival predictors for patients receiving CD19-directed CAR-T. Patients (n = 514) from 13 centers treated with CAR-T for B-NHL between 2015-2021 were included in the study. Survival curves were constructed using Kaplan-Meier method. Multivariate Cox regression analysis was used to determine the impact of the variables on survival outcomes. For all patients receiving CAR-T, a greater number of lines of therapy pre-CAR-T apheresis and bridging therapy were predictive of inferior progression-free survival (PFS) and overall survival (OS). The median PFS and OS from the time of CAR-T cell infusion were 7.6 and 25.6 months, respectively. From the time of progression post-CAR-T, the median OS was 5.5 months. The median PFS of treatments administered in the first-line post-CAR-T failure was 2.8 months. Patients with refractory disease on day 30 had inferior OS and were less likely to receive subsequent treatment(s) than other patients with CAR-T failure. Allogeneic hematopoietic cell transplantation for selected patients at any time following CAR-T failure led to durable responses in over half of patients at 1 year. These data provide a benchmark for future clinical trials in patients with post-CAR-T cell progression, which remains an unmet clinical need.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Zurko J, Nizamuddin I, Epperla N, et al. Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL. Blood Adv. 2023. PMID: 36094847. doi:10.1182/bloodadvances.2022008240

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。